Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: A 12-month, open-label extension study

CNS Drugs

Volumn 21, Issue 5, 2007, Pages 407-416

  Hirshkowitz, Max ^a   Black, Jed ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL; PLACEBO;

ADULT; AGED; ANXIETY; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEALTH BEHAVIOR; HUMAN; INFECTION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PAIN; PATIENT EDUCATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SHORT FORM 36; SIDE EFFECT; SINUSITIS; SLEEP APNEA SYNDROME; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WAKEFULNESS;

BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP APNEA, OBSTRUCTIVE; SLEEP STAGES; TREATMENT OUTCOME; WAKEFULNESS;

EID: 34247891776     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721050-00004     Document Type: Article

References (41)

1. Olson EJ, Moore WR, Morgenthaler TI, et al. Obstructive sleep apnea-hypopnea syndrome. Mayo Clin Proc 2003; 78: 1545-52
2. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291 (16): 2013-6
3. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993 1993; 328 (17): 1230-5
4. Seneviratne U, Puvanendran K. Excessive daytime sleepiness in obstructive sleep apnea: prevalence, severity, and predictors. Sleep Med 2004; 5: 339-43
5. Bedard MA, Montplaisir J, Malo J, et al. Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airways pressure (CPAP). J Clin Exp Neuropsychol 1993; 15: 330-41
6. Naegele B, Thouvard V, Pepin JL, et al. Deficits of cognitive executive functions in patients with sleep apnea syndrome. Sleep 1995; 18 (1): 43-52
7. Gliklich RE, Taghizadeh F, Winkelman JW. Health status in patients with disturbed sleep and obstructive sleep apnea. Otolaryngol Head Neck Surg 2000; 122: 542-6
8. Barbé F, Pericás J, Muñoz A, et al. Automobile accidents in patients with sleep apnea syndrome: an epidemiological and mechanistic study. Am J Respir Crit Care Med 1998; 158: 18-22
9. Ulfberg J, Carter N, Edling C. Sleep-disordered breathing and occupational accidents. Scand J Work Environ Health 2000; 26: 237-42
10. Engleman H, Joffe D. Neuropsychological function in obstructive sleep apnoea. Sleep Med Rev 1999; 3 (1): 59-78
11. Engleman HM, Martin SE, Deary IJ, et al. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome. Lancet 1994; 343: 572-5
12. Jenkinson C, Davies RJ, Mullins R, et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100-5
13. D'Ambrosio C, Bowman T, Mohsenin V. Quality of life in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure: a prospective study. Chest 1999; 115: 123-9
14. Bennett LS, Barbour C, Langford B, et al. Health status in obstructive sleep apnea: relationship with sleep fragmentation and daytime sleepiness, and effects of continuous positive airway pressure treatment. Am J Respir Crit Care Med 1999; 159: 1884-90
15. Sforza E, Krieger J. Daytime sleepiness after long-term continuous positive airway pressure (CPAP) treatment in obstructive sleep apnea syndrome. J Neurol Sci 1992; 110: 21-6
16. Black J, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005; 28: 464-71
17. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164 (9): 1675-81
18. Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998; 241 (2-3): 95-8
19. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996; 93 (24): 14128-33
20. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67 (4): 554-66
21. Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27 (1): 19-25
22. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20 (22): 8620-8
23. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132 (4): 1027-34
24. de Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001; 12 (16): 3533-7
25. Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001; 163 (4): 918-23
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14 (6): 540-5
27. Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997; 20 (10): 835-43
28. Ware J. SF-36 health survey update [online]. Available from URL: http://www.sf-36.org/tools/sf36.shtml [Accessed 2005 July 20]
29. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 2003; 4 (5): 393-402
30. Schwartz JR, Hirshkowitz M, Erman MK, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003; 124 (6): 2192-9
31. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22 (6): 757-65
32. Engleman HM, Martin SE, Douglas NJ. Compliance with CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax 1994; 49: 263-6
33. Reeves-Hoche MK, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994; 149: 149-54
34. Krieger J. Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapneic snorers. Sleep 1992; 15 (6 Suppl.): S42-6
35. Pieters T, Collard P, Aubert G, et al. Acceptance and long-term compliance with nCPAP in patients with obstructive sleep apnoea syndrome. Eur Respir J 1996; 9 (5): 939-44
36. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365 (9464): 1046-53
37. Schiza SE, Fraggedaki A, Basta M, et al. The use of modafinil in patients with obstructive apnea hypopnea syndrome: a randomized, placebo-controlled, double-blind study. Sleep 2001; 24 Suppl.: A10-1
38. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342 (19): 1378-84
39. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000; 283: 1829-36
40. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14
41. Heitmann J, Cassel W, Grote L, et al. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? Clin Pharmacol Ther 1999; 65 (3): 328-35